Sugi Predict

Sugi Predict / Compounds / SCHEMBL638086

SCHEMBL638086

SCHEMBL638086

Cc1cc2ccccc2c[n+]1[O-]

nearest known ligand 0.47

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ CYP2D6 P10635 1/20 0.47
▸ HSD17B10 Q99714 1/20 0.47
▸ CYP2A6 P11509 3/20 0.39
▸ TDP1 Q9NUW8 2/20 0.39
▸ ATM Q13315 1/20 0.38
▸ CYP1A2 P05177 2/20 0.35
▸ L3MBTL1 Q9Y468 3/20 0.35
▸ KDM4E B2RXH2 4/20 0.34
▸ ALDH1A1 P00352 3/20 0.34
▸ LMNA P02545 2/20 0.34
▸ GAA P10253 2/20 0.33
▸ PTGS2 P35354 1/20 0.32
▸ HPGD P15428 1/20 0.32
▸ STAT3 P40763 1/20 0.32
▸ MEN1 O00255 1/20 0.32
▸ MAPT P10636 1/20 0.32
▸ KMT2A Q03164 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31094415 1.00 CYP2D6 (0.47) CYP2D6HSD17B10CYP2A6TDP1ATM
SCHEMBL2422493 0.76 ATM (0.41) CYP2D6HSD17B10CYP2A6TDP1ATM
SCHEMBL28316555 0.74 CYP2D6 (0.53) CYP2D6HSD17B10CYP2A6TDP1CYP1A2
SCHEMBL1048904 0.74 CYP2D6 (0.48) CYP2D6HSD17B10CYP2A6TDP1CYP1A2
SCHEMBL10981311 0.73 CYP2A6 (0.39) CYP2D6HSD17B10CYP2A6TDP1ATM
SCHEMBL27646855 0.73 CYP2D6 (0.47) CYP2D6HSD17B10CYP2A6TDP1CYP1A2
SCHEMBL26202229 0.73 CYP2D6 (0.47) CYP2D6HSD17B10CYP2A6TDP1CYP1A2
SCHEMBL9332297 0.73 CYP2D6 (0.47) CYP2D6HSD17B10CYP2A6TDP1CYP1A2
Iodide SCHEMBL7251052 0.73 CYP2D6 (0.47) CYP2D6HSD17B10CYP2A6TDP1CYP1A2
SCHEMBL1536372 0.73 CYP2A6 (0.39) CYP2D6HSD17B10CYP2A6TDP1ATM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 85 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1104417-A4 IMPROVED OMEPRAZOLE PROCESS AND COMPOSITIONS THEREOF ASTRAZENECA AB (SE) 2002-12-18 — — EP claimed
EP-1104417-A1 IMPROVED OMEPRAZOLE PROCESS AND COMPOSITIONS THEREOF Merck & Co., Inc. (US) 2001-06-06 — — EP claimed
US-6166213-A Omeprazole process and compositions thereof MERCK & CO., INC. (US) 2000-12-26 — — US claimed
WO-2000009497-A1 IMPROVED OMEPRAZOLE PROCESS AND COMPOSITIONS THEREOF MERCK & CO., INC. (US) 2000-02-24 — — WO claimed
EP-4536356-A1 PYRIDINAMINE DERIVATIVES AND THEIR USE AS POTASSIUM CHANNEL MODULATORS Xenon Pharmaceuticals Inc. (CA) 2025-04-16 — — EP disclosed
EP-3558969-B1 PYRAZOLE DERIVATIVES AS MALT1 INHIBITORS JANSSEN PHARMACEUTICA NV (BE) 2024-09-18 — — EP disclosed
US-12077521-B2 Pyrazole derivatives as MALT1 inhibitors JANSSEN PHARMACEUTICA NV (BE) 2024-09-03 — — US disclosed
US-20240101531-A1 PYRIDINAMINE DERIVATIVES AND THEIR USE AS POTASSIUM CHANNEL MODULATORS XENON PHARMACEUTICALS INC. (CA) 2024-03-28 — — US disclosed
WO-2023239729-A1 PYRIDINAMINE DERIVATIVES AND THEIR USE AS POTASSIUM CHANNEL MODULATORS XENON PHARMACEUTICALS INC. (CA) 2023-12-14 — — WO disclosed
WO-2023239729-A1 PYRIDINAMINE DERIVATIVES AND THEIR USE AS POTASSIUM CHANNEL MODULATORS XENON PHARMACEUTICALS INC. (CA) 2023-12-14 — — WO disclosed
US-20220315557-A1 PYRAZOLE DERIVATIVES AS MALT1 INHIBITORS JANSSEN BIOTECH, INC. 2022-10-06 — — US disclosed
US-10954214-B2 Pyrazole derivatives as MALT1 inhibitors JANSSEN PHARMACEUTICA NV (BE) 2021-03-23 — — US disclosed
EP-1240159-A4 IMPROVED OMEPRAZOLE PROCESS AND COMPOSITIONS THEREOF ASTRAZENECA AB (SE) 2003-04-16 — — EP disclosed
EP-1104417-A4 IMPROVED OMEPRAZOLE PROCESS AND COMPOSITIONS THEREOF ASTRAZENECA AB (SE) 2002-12-18 — — EP disclosed
EP-1240159-A1 IMPROVED OMEPRAZOLE PROCESS AND COMPOSITIONS THEREOF Merck & Co., Inc. (US) 2002-09-18 — — EP disclosed
WO-2001044231-A1 IMPROVED OMEPRAZOLE PROCESS AND COMPOSITIONS THEREOF MERCK & CO., INC. (US) 2001-06-21 — — WO disclosed
EP-1104417-A1 IMPROVED OMEPRAZOLE PROCESS AND COMPOSITIONS THEREOF Merck & Co., Inc. (US) 2001-06-06 — — EP disclosed
US-6166213-A Omeprazole process and compositions thereof MERCK & CO., INC. (US) 2000-12-26 — — US disclosed
US-6147103-A Extremely low residual solvent content MERCK & CO., INC. (US) 2000-11-14 — — US disclosed
WO-2000009497-A1 IMPROVED OMEPRAZOLE PROCESS AND COMPOSITIONS THEREOF MERCK & CO., INC. (US) 2000-02-24 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220315557-A1 PYRAZOLE DERIVATIVES AS MALT1 INHIBITORS MALT1, PPP3R1, SQSTM1 CYP2D6 875/4885HSD17B10 1485/4885CYP2A6 1608/4885
US-20240101531-A1 PYRIDINAMINE DERIVATIVES AND THEIR USE AS POTASSIUM CHANNEL MODULATORS KCNA1, KCNB1, KCNB2 CYP2D6 197/4885HSD17B10 3551/4885CYP2A6 740/4885
US-10954214-B2 Pyrazole derivatives as MALT1 inhibitors MALT1, PPP3R1, SQSTM1 CYP2D6 875/4885HSD17B10 1485/4885CYP2A6 1608/4885
US-12077521-B2 Pyrazole derivatives as MALT1 inhibitors MALT1, PPP3R1, SQSTM1 CYP2D6 875/4885HSD17B10 1485/4885CYP2A6 1608/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.